Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (635)	4/25/1997 1:35:00 PM
From: Jorgen Jensen	of 6136

To all, Perhaps this announcement has something to do with the carnage: Wednesday April 23 6:54 PM EDT Merck( Merck & Co Inc ) says working on new anti-AIDS therapy BRANCHBURG, N.J., April 23 (Reuter) - Merck and Co Inc said on Wednesday researchers were working on a new combination therapy to fight HIV, the virus that causes AIDS. The new treatment combines Merck's Crixivan, a protease inhibitor, and a compond known as DMP-266, being developed by a DuPont Co ( E.I. Du Pont De Nemours & Co (DuPont) )-Merck joint venture, Merck researchers told shareholders at the company's annual meeting. DMP-266 is non-nucleoside reverse transcriptase inhibitor. Edward Scolnick, president of Merck Research Laboratories, said the new combination is "what we believe is a new regimen for treating HIV." In preliminary studies, the new dual therapy had shown to be more effective than triple therapies using a protease inhibitor in combination with two older-line anti-HIV drugs, he said. The triple therapies have been shown effective in sharply reducing the level of HIV in the bloodstream.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next